Amar Rewari, Chief of Radiation Oncology at Luminis Health, shared a post on LinkedIn:
“Advancements in Advanced Prostate Cancer: The Shift from Cure to Control and Quality of Life
In my recent interview with Patient Power, we discussed how advances in systemic therapy and radiation are reshaping care for men with advanced prostate cancer. The focus today is long-term control, better survival, and preserving quality of life.
Most patients with metastatic hormone sensitive prostate cancer now start with androgen deprivation therapy plus agents like apalutamide or abiraterone.
These combinations delay progression and improve outcomes, while tumor biology, genomics, and patient goals guide personalization.
Radiation continues to play a central role, especially for painful bone metastases.
As I shared in the interview:
‘Radiation is one of the most effective ways to relieve pain from bone metastases… Most patients begin to feel improvement within one to two weeks, and the benefit can last for months or longer.’
And importantly:
‘For advanced prostate cancer, radiation complements, not replaces, systemic therapies.’
Newer options like Pluvicto and SBRT are driving even more coordinated, comprehensive care.
What advancement over the past five years has made the biggest impact in your practice?
You can read the full article.“
More posts featuring Amar Rewari.